Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease.

Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarkers to predict the IFX effect for Japanese Crohn's disease (CD) patients by performing an association study of single nucleotide polymorphisms (SNPs) in candidate genes in the interleukin- (IL-) 17 sign...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International Vol. 2015; pp. 1 - 13
Autores principales: Shigetoshi Urabe, Hajime Isomoto, Tetsuya Ishida, Kazumi Maeda, Tatsuo Inamine, Shinji Kondo, Norihide Higuchi, Kayoko Sato, Ryohei Uehara, Hiroyuki Yajima, Haruhisa Machida, Chun Chuan Chen, Yasuhiro Fukuda, Fuminao Takeshima, Kazuhiko Nakao, Kazuhiro Tsukamoto
Formato: algorithm pictorial research tables/charts Journal Article
Publicado: Wiley-Blackwell 10/19/2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128652113&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 128652113
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 10/19/2015
      vid: 2015
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        128652113
        128652113
        128652113
        10.1155/2015/416838
        128652113
      ppf: 1
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn's Disease.
      aug:
        au:
          Shigetoshi Urabe
          Hajime Isomoto
          Tetsuya Ishida
          Kazumi Maeda
          Tatsuo Inamine
          Shinji Kondo
          Norihide Higuchi
          Kayoko Sato
          Ryohei Uehara
          Hiroyuki Yajima
          Haruhisa Machida
          Chun Chuan Chen
          Yasuhiro Fukuda
          Fuminao Takeshima
          Kazuhiko Nakao
          Kazuhiro Tsukamoto
        affil: Department of Gastroenterology and Hepatology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
      sug:
        subj:
          Polymorphism, Genetic Drug Effects
          Interleukins Drug Effects
          Antibodies, Monoclonal Pharmacodynamics
          Crohn Disease Familial and Genetic
          Biological Markers
          Nucleotides Drug Effects
          Signal Transduction Drug Effects
          Human
          Japan
          Genotype
          Alleles
          Genetic Screening
          Multivariate Analysis
          Logistic Regression
          Immunologic Factors
      ab: Background. We aimed to identify certain genes related to response to infliximab (IFX) and biomarkers to predict the IFX effect for Japanese Crohn's disease (CD) patients by performing an association study of single nucleotide polymorphisms (SNPs) in candidate genes in the interleukin- (IL-) 17 signaling pathway with response to IFX after 1 year of treatment. Methods. A total of 103 patients were divided into two groups, responders and nonresponders. Twenty-eight tag SNPs in 5 genes were genotyped. The frequencies of alleles and genotypes of each SNP were compared between responders and nonresponders in three different inheritance models. A genetic test was performed using a combination of the associated SNPs as biomarkers. Results. Multivariate logistic regression analysis indicated that the four variable factors, concomitant use of immunomodulators, penetrating disease, a G/G genotype of rs766748 in IL-17F, and a C/C or C/A genotype of rs1883136 in TRAF3IP2, independently contributed to response to IFX after 1 year of treatment. Genetic test using the polymorphisms of these genes perfectly predicted the responder and nonresponder CD patients with both concomitant use of immunomodulators and penetrating disease. Conclusion. IL17F and TRAF3IP2 are one of IFX-related genes, useful as biomarkers of IFX response, and may be target molecules for new therapeutic drugs.
      pubtype: Academic Journal
      doctype:
        algorithm
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N